Death, recurrence in NSCLC not tied to opioid usage
Opioid usage is not associated with long-term outcomes such as death and risk of recurrence in non-small cell lung cancer (NSCLC) patients, a new study has found.
The study included 871 NSCLC patients stratified into quartiles according to opioid use. Only patients who underwent sleeve lobectomy, bilobectomy or lobectomy were included. Exclusion criteria included death, need for revision surgery, occurrence of a different primary cancer within 5 years and incomplete medical records.
Multivariate logistic regression models showed that opioid dosage was not associated with either recurrence (Wald chi-square, 0.4128; p=0.520) or death (Wald chi square, 0.1939; p=0.659). However, when taking cancer stage into account, opioid use was significantly correlated with recurrence (p=0.004) and death (p=0.049).
A 1-unit increase in opioid dosage was correlated with a significant increase in recurrence for cancer stages IA (odds ratio [OR], 1.001; 95 percent CI, 1.001 to 1.001; p=0.004), IB (OR, 1.001; 1.000 to 1.001; p=0.02) and IB (OR, 1.001; 1.001 to 1.002; p=0.0006).
Similar significant increases in the risk of death in cancer stages IA (OR, 1.001; 1.000 to 1.001; p=0.0105), IB (OR, 1.001; 1.000 to 1.001; p=0.0317) and IIB (OR, 1.001; 1.000 to 1.001; p=0.0363) were calculated with a 1-unit increase in opioid dosage.
However, because of the small magnitude of the ORs, it may be concluded that opioid usage does not affect risk of death or recurrence in NSCLC regardless of stage, researchers said.